Neoadjuvant immunotherapy (talimogene laherparepvec) vs no neoadjuvant treatment
Death Number of deaths over 36 months · stage III and IV cutaneous melanoma
It is very uncertain whether neoadjuvant immunotherapy (talimogene laherparepvec) changes overall survival (OS), measured by the number of deaths over time, compared with no neoadjuvant treatment (very low certainty).
1 finding from 1 review
- Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes onlyHR 0.49 [0.15, 1.64]1 study · 150 participantsVery low